Press releases

23 May, 2017

Regulatory

NeuroVive to continue NeuroSTAT® clinical development after positive outcome in preclinical and clinical TBI studies

Lund, Sweden, 23 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced positive results from clinical and preclinical studies with its drug NeuroSTAT® for the pr ...

18 May, 2017

Regulatory

NeuroVive Pharmaceutical AB Interim report January – March 2017

Broadened project portfolio

2 May, 2017

Regulatory

NeuroVive in-licenses a genetic mitochondrial disease clinical stage project from Yungjin Pharm

Lund, Sweden and Seoul, Korea, 2 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly ann ...

20 April, 2017

Regulatory

NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects

Lund, Sweden, 20 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical results demonstrating anti-fibrotic effects with NV55 ...

5 April, 2017

Regulatory

NeuroVive’s lead NASH project to be presented at The International Liver Congress™

Lund, Sweden, April 5, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with preclinical data related to t ...

23 March, 2017

Regulatory

NeuroVive Pharmaceutical AB publishes 2016 Annual report

Lund, Sweden, March 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for ...

22 February, 2017

Regulatory

NeuroVive appoints recognized scientific advisors and enters research agreements in NASH and hepatocellular carcinoma

Lund, Sweden, February 22, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced two new research agreements and the appointment ...

21 February, 2017

Regulatory

NeuroVive Pharmaceutical AB Year End Report January – December 2016

Important steps forward and new research collaborations

2 February, 2017

Regulatory

NeuroVive’s new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells

Lund, Sweden, February 2, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, presents preclinical data from a new generation of sanglifehrin- ...

25 January, 2017

Regulatory

NeuroVive redirects research resources from Asian subsidiary to parent

Lund, Sweden, January 25, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its Taiwan-based subsidiary's research reso ...

23 January, 2017

Regulatory

NeuroVive signs mitochondrial medicine research agreement with US key opinion leader

Lund, Sweden, January 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announces that NeuroVive has signed a preclinical collaboration agreement with the Children's ...

19 January, 2017

Regulatory

NeuroVive presents positive preclinical data in hepatocellular cancer at HCC Summit

Lund, Sweden, January 19, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer d ...